Jens Meiler

July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

By Tom Wilemon
February 2, 2022

VUMC’s Knollman, Ware among new AAAS Fellows

Vanderbilt’s Ware, Knollman among new American Association for the Advancement of Science Fellows.

By Kathy Whitney
Benjamin Brown, left, Jens Meiler, PhD, Zhenfang Du, PhD, and colleagues are studying the functional consequences of genetic mutations and how those changes can drive cancerous growth.
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

By Bill Snyder
From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

By Tom Wilemon
January 31, 2019

Designing antibodies to fight the flu

Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.

By Bill Snyder
August 11, 2016

Transcription factor evolution

Vanderbilt researchers have discovered a novel model of evolution for factors that control gene expression.

By Sanjay Mishra
June 2, 2016

‘Young Scientist’ showcases high schoolers’ research at Vanderbilt

High school students performing advanced research at Vanderbilt have the opportunity to share their findings with the scientific community through a journal of their own.
By VUMC News and Communications
April 7, 2016

Potent HIV antibodies suggest new vaccine development approach

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
By Bill Snyder
February 5, 2016

Dynamics of a drug resistance transporter

Vanderbilt investigators are exploring the shape changes in a multidrug transporter to understand the mechanisms of antibacterial resistance.
By VUMC News and Communications
May 21, 2015

‘Redesigned’ antibodies may control HIV: study

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
By Bill Snyder
May 15, 2015

VU lands $9 million NIH grant to design better flu vaccines

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.
By Bill Snyder
October 27, 2014

Members named to Academic Strategic Plan committees

Two committees tasked with fleshing out key initiatives in Vanderbilt’s Academic Strategic Plan are now staffed and ready to begin work.
By VUMC News and Communications
December 2, 2013

VU researchers report G protein advancement that could lead to more effective drugs

Thanks in part to a computer program named “Rosetta,” Vanderbilt University researchers are closer to understanding how the ubiquitous G protein is activated – a discovery that could lead to the design of more specific and effective drugs.
By Bill Snyder
1 2